pravastatin has been researched along with Liver Dysfunction in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sano, N; Sasamoto, T; Takikawa, H | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Alsheikh-Ali, AA; Han, H; Karas, RH; Maddukuri, PV | 1 |
| Belder, R; Fusco, MJ; Lewis, JH; Medoff, JR; Mortensen, ME; Zweig, S | 1 |
| Braunwald, E; Byington, RP; Cobbe, SM; Davis, BR; Friedman, CP; Keech, A; Pfeffer, MA; Sacks, FM; Tonkin, A | 1 |
| Pan, HY | 1 |
2 review(s) available for pravastatin and Liver Dysfunction
| Article | Year |
|---|---|
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.
Topics: Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver Diseases; Lovastatin; Neoplasms; Pravastatin; Rhabdomyolysis; Simvastatin | 2007 |
Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase.
Topics: Anticholesteremic Agents; Cholelithiasis; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lactation; Liver Diseases; Naphthalenes; Pravastatin; Reference Values | 1991 |
1 trial(s) available for pravastatin and Liver Dysfunction
| Article | Year |
|---|---|
Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Double-Blind Method; Female; Humans; Hypercholesterolemia; Liver; Liver Diseases; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2007 |
3 other study(ies) available for pravastatin and Liver Dysfunction
| Article | Year |
|---|---|
Biliary excretion of sulfated bile acids and organic anions in zone 1- and zone 3-injured rats.
Topics: Animals; Anions; ATP-Binding Cassette Transporters; Bile; Bile Acids and Salts; Biliary Tract; Biological Transport; Bromobenzenes; Chemical and Drug Induced Liver Injury; Liver; Liver Diseases; Male; Phenolphthaleins; Pravastatin; Propanols; Rats; Rats, Sprague-Dawley; Taurolithocholic Acid | 2006 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.
Topics: Aged; Anticholesteremic Agents; Breast Neoplasms; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cohort Studies; Comorbidity; Demography; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Liver Diseases; Male; Middle Aged; Multivariate Analysis; Muscular Diseases; Pravastatin; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency; Risk; Risk Assessment; Time | 2002 |